Brief: Castle Biosciences Says Tissuecypher Test Results Can Increase The Likelihood Of Appropriate Management Decisions For Barrett's Esophagus Patients With Low-Grade Dysplasia
20/04/2023 13:29
April 20 (Reuters) - Castle Biosciences Inc CSTL.O :
* TISSUECYPHER® TEST RESULTS CAN INCREASE THE LIKELIHOOD OF
APPROPRIATE MANAGEMENT DECISIONS FOR BARRETT’S ESOPHAGUS
PATIENTS WITH LOW-GRADE DYSPLASIA
Source text for Eikon: ID:nBwbZGlRa
Further company coverage: CSTL.O
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Castle Biosciences
See all newsBrief: Castle Biosciences, - Opens New Laboratory And Office Facility In Scottsdale, Arizona
U.S. RESEARCH ROUNDUP-Abbvie, Amazon, Illumina
Castle Biosciences Inc reports results for the quarter ended June 30 - Earnings Summary
Castle Biosciences beats Q2 revenue estimates, hikes forecast
Brief: Castle Biosciences Q2 Revenue USD 103.546 Million Vs. IBES Estimate USD 86.2 Million